Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Renal Failure: full-pipeline trial registry

4 of 12 indexed Renal Failure trials are currently recruiting.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 4 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Renal Failure: 12 US clinical trials tracked, 4 recruiting.

Renal Failure is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Veloxis Pharmaceuticals, running 2 of these trials.

Enrollment posture brief

Registry condition renal-failure

OPEN 4 | RECR 33% | LATE 3 | EARLY 3 | RANK #1429 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Renal Failure (this)33%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Renal Failure

Renal Failure lists 4 open slots (33% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Renal Failure on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Renal Failure is recruiting below its size-band peers.

    4 of 12 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Renal Failure research.

    Veloxis Pharmaceuticals accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Renal Failure trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.

  4. Renal Failure research is mostly interventional.

    10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21Phase 32Phase 41

Open and recent trials

12 total, page 1 of 1

RECRUITING NA 600 participants

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

VenoStent

NCT06001827

RECRUITING Phase 2 242 participants

Prevent Cardiac Surgery Associated AKI Trial

George Washington University

NCT06620523

RECRUITING Early Phase 1 30 participants

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Augusta University

NCT06142396

RECRUITING NA 20 participants

Post-Filter Hematocrit

Gwyndolyn M. Radford

NCT07293936

ACTIVE NOT RECRUITING Phase 1 20 participants

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Massachusetts General Hospital

NCT04540380

COMPLETED NA 1,915 participants

Improving Patient Prioritization During Hospital-homecare Transition

Columbia University

NCT04136951

COMPLETED Phase 3 326 participants

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Veloxis Pharmaceuticals

NCT00817206

COMPLETED Phase 4 70 participants

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Genzyme, a Sanofi Company

NCT00123461

COMPLETED Phase 3 50 participants

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Veloxis Pharmaceuticals

NCT01962922

COMPLETED NA 20 participants

Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure

Vanderbilt University Medical Center

NCT02128802

COMPLETED 18 participants

Pharmacokinetics of Antiepileptics in Patients on CRRT

University of Maryland, Baltimore

NCT03632915

COMPLETED 5 participants

Daptomycin Study - Collection of Pharmacokinetic Samples in Patients With Renal Failure

University of Pittsburgh

NCT00573898

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Renal Failure records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

LCP-Tacro Drug
2 trials
Prograf Drug
1 trials
PREVENT clinical decision support Other
1 trials
Tacrolimus -IR Drug
1 trials
Phenobarbital Drug
1 trials
Hectorol (doxercalciferol capsules), 0.5mcg Drug
1 trials
Weight Loss Program Other
1 trials
Phenytoin Drug
1 trials

US sites by state

Facility locations filed on Renal Failure trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
New York 3 trials
California 3 trials
North Carolina 2 trials
Missouri 2 trials
Minnesota 2 trials
Massachusetts 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Renal Failure page

12 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Failure condition card totals 12 registered trials; most-linked intervention LCP-Tacro; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.